{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:08:03Z","timestamp":1791544083771,"version":"4.3.4"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Rationale<\/jats:title><jats:p>Therapies that slow idiopathic pulmonary fibrosis (IPF) progression are now available and recent studies suggest that the use of antifibrotic therapy may reduce IPF mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The aim of the study was to evaluate whether, to what extent, and for which factors the survival of IPF in a real-life setting has changed in the last 15 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Historical eye is an observational study of a large cohort of consecutive IPF patients diagnosed and treated in a referral center for ILDs with prospective intention. We recruited all consecutive IPF patients seen at GB Morgagni Hospital, Forl\u00ec, Italy between January 2002 and December 2016 (15 years). We used survival analysis methods to describe and model the time to death or lung transplant and Cox regression to model prevalent and incident patient characteristics (time-dependent Cox models were fitted).<\/jats:p><\/jats:sec><jats:sec><jats:title>Measurements and main results<\/jats:title><jats:p>The study comprised 634 patients. The year 2012 identifies the time point of mortality shift (HR 0.58, CI 0.46\u20130.63, <jats:italic>p<\/jats:italic> &amp;lt; 0.001). In the more recent cohort, more patients had better preserved lung function, underwent cryobiopsy instead of surgery, and were treated with antifibrotics. Highly significant negative prognostic factors were lung cancer (HR 4.46, 95% CI 3.3\u20136, <jats:italic>p<\/jats:italic> &amp;lt; 0.001), hospitalizations (HR 8.37, 95% CI 6.5\u201310.7, <jats:italic>p<\/jats:italic> &amp;lt; 0.001), and acute exacerbations (HR 8.37, 95% CI 6.52\u201310.7, <jats:italic>p<\/jats:italic> &amp;lt; 0.001). The average antifibrotic treatment effect estimated using propensity score matching showed a significant effect in the reduction of all-cause mortality (ATE coeff \u22120.23, SE 0.04, <jats:italic>p<\/jats:italic> &amp;lt; 0.001), acute exacerbations (ATE coeff \u22120.15, SE 0.04, <jats:italic>p<\/jats:italic> &amp;lt; 0.001), and hospitalizations (ATE coeff \u22120.15, SE 0.04, <jats:italic>p<\/jats:italic> &amp;lt; 0.001) but no effect on lung cancer risk (ATE coeff \u22120.03, SE 0.03, <jats:italic>p<\/jats:italic> = 0.4).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Antifibrotic drugs significantly impact hospitalizations, acute exacerbations, and IPF survival. After the introduction of cryobiopsy and antifibrotic drugs, the prognosis of IPF patients has significantly improved together with our ability to detect IPF at an earlier stage.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1151922","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T14:40:16Z","timestamp":1685716816000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Historical eye on IPF: a cohort study redefining the mortality scenario"],"prefix":"10.3389","volume":"10","author":[{"given":"Sara","family":"Tomassetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Ravaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Piciucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athol","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Donati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Dubini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Klersy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Luzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Rosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Lavorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venerino","family":"Poletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1702618","DOI":"10.1080\/20018525.2019.1702618","article-title":"Forced Vital Capacity (FVC) decline, mortality and healthcare resource utilization in idiopathic pulmonary fibrosis","volume":"7","author":"Lassenius","year":"2020","journal-title":"Eur Clin Respir J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report","volume":"194","author":"Kishaba","year":"2016","journal-title":"Am J Respir Crit Care Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1378\/chest.14-0359","article-title":"The impact of lung cancer on survival of idiopathic pulmonary fibrosis","volume":"147","author":"Tomassetti","year":"2015","journal-title":"Chest."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King Jr","year":"2014","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1183\/13993003.01966-2015","article-title":"Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function","volume":"48","author":"Albera","year":"2016","journal-title":"Eur Respir J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1136\/thoraxjnl-2016-208710","article-title":"Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume","volume":"72","author":"Kolb","year":"2017","journal-title":"Thorax."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1056\/NEJMoa1811737","article-title":"Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis","volume":"379","author":"Kolb","year":"2018","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1164\/rccm.201311-1951OC","article-title":"All-cause mortality rate in patients with idiopathic pulmonary fibrosis Implications for the design and execution of clinical trials","volume":"189","author":"King Jr","year":"2014","journal-title":"Am J Respir Crit Care Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1183\/13993003.01592-2016","article-title":"Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry","author":"Jo","year":"2017"},{"key":"B12","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1183\/13993003.00026-2015","article-title":"Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials","volume":"47","author":"Noble","year":"2016","journal-title":"Eur Respir J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1183\/13993003.01339-2016","article-title":"Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis","author":"Collard","year":"2017"},{"key":"B14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S2213-2600(16)30326-5","article-title":"Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis","volume":"5","author":"Nathan","year":"2017","journal-title":"Lancet Respir Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e0136160","DOI":"10.1371\/journal.pone.0136160","article-title":"Pirfenidone for idiopathic pulmonary fibrosis: a systematic review and meta-analysis","volume":"10","author":"Aravena","year":"2015","journal-title":"PLoS ONE."},{"key":"B16","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.18553\/jmcp.2017.23.3-b.s5","article-title":"Systematic review and network meta-analysis of idiopathic pulmonary fibrosis treatments","volume":"23","author":"Fleetwood","year":"2017","journal-title":"J Manag Care Spec Pharm."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S2213-2600(16)30416-7","article-title":"Pirfenidone and mortality in idiopathic pulmonary fibrosis","volume":"5","author":"Spagnolo","year":"2017","journal-title":"Lancet Respir Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.chest.2020.08.016","article-title":"Mortality Trends of Idiopathic Pulmonary Fibrosis in the United States From 2004 Through 2017","volume":"159","author":"Jeganathan","year":"2021","journal-title":"Chest."},{"key":"B19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12931-018-0845-5","article-title":"The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis","volume":"19","author":"Guenther","year":"2018","journal-title":"Respir Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12931-019-1271-z","article-title":"The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis","volume":"21","author":"Tran","year":"2020","journal-title":"Respir Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1159\/000490667","article-title":"Identifying barriers to idiopathic pulmonary fibrosis treatment: a survey of patient and physician views","volume":"96","author":"Maher","year":"2018","journal-title":"Respiration."},{"key":"B22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S2213-2600(17)30433-2","article-title":"Diagnostic criteria for idiopathic pulmonary fibrosis: a fleischner society white paper","volume":"6","author":"Lynch","year":"2018","journal-title":"Lancet Respir Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1164\/rccm.201104-0668OC","article-title":"Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study","volume":"184","author":"Lamas","year":"2011","journal-title":"Am J Respir Crit Care Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1164\/rccm.201701-0091OC","article-title":"Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis","volume":"196","author":"Ley","year":"2017","journal-title":"Am J Respir Crit Care Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1164\/rccm.201902-0456OC","article-title":"Clinical effectiveness of antifibrotic medications for idiopathic pulmonary fibrosis","volume":"200","author":"Dempsey","year":"2019","journal-title":"Am J Respir Crit Care Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.resinv.2017.09.007","article-title":"Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone","volume":"56","author":"Miura","year":"2018","journal-title":"Respir Investig."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","article-title":"Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis","volume":"366","author":"Idiopathic Pulmonary Fibrosis Clinical Research","year":"2012","journal-title":"N Engl J Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1183\/09031936.00009112","article-title":"Triple therapy in idiopathic pulmonary fibrosis: an alarming press release","volume":"39","author":"Wells","year":"2012","journal-title":"Eur Respir J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1183\/09059180.00006812","article-title":"Interstitial lung disease","volume":"22","author":"Cottin","year":"2013","journal-title":"Eur Respir Rev."},{"key":"B31","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s12890-020-01328-y","article-title":"In-hospital mortality trends among patients with idiopathic pulmonary fibrosis in the United States between 2013-2017: a comparison of academic and non-academic programs","volume":"20","author":"Alqalyoobi","year":"2020","journal-title":"BMC Pulm Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1164\/rccm.201508-1546OC","article-title":"Predictors of mortality poorly predict common measures of disease progression in idiopathic pulmonary fibrosis","volume":"194","author":"Ley","year":"2016","journal-title":"Am J Respir Crit Care Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1164\/rccm.201011-1790OC","article-title":"Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis","volume":"184","author":"du Bois","year":"2011","journal-title":"Am J Respir Crit Care Med."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1151922\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T14:40:18Z","timestamp":1685716818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1151922\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":33,"alternative-id":["10.3389\/fmed.2023.1151922"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1151922","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,2]]},"article-number":"1151922"}}